retatrutide phase 2 results 2024 2025 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide: Phase 3 Results (Up

Many are reporting a decrease in mental chatter and urges or compulsive cravings

Although costs of some have gone down recently, branded GLP-1s are typically $499/month and up, if you are paying out of pocket

You should contact your GP or NHS 111 if you experience severe, persistent vomiting or diarrhoea that prevents you from keeping down fluids, as this can lead to dehydration and electrolyte imbalance

In the UK, D-allulose is classified as a novel food and requires authorisation from the Food Standards Agency (FSA) before widespread commercial use, with specific conditions of use that must be followed

Report symptoms like decreased urination, swelling, or fatigue to your healthcare provider immediately